Clinical Trials Logo

Urogenital Abnormalities clinical trials

View clinical trials related to Urogenital Abnormalities.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03295175 Withdrawn - Clinical trials for Congenital Urogenital Anomaly

Distribution of Smooth Muscle In Dartos In The Non Conspicuous Penis

DISMUD
Start date: September 21, 2017
Phase:
Study type: Observational [Patient Registry]

Non-conspicuous penis (congenital megaprepuce, occult penis) is a symptomatic malformation that includes phimosis and excessively baggy, urine-filled prepuce with alteration of the appearance of the penis. A redundant and enlarged foreskin is the main feature of this entity.This congenital anomaly is difficult to diagnose and may have association with other pathologies such as buried penis. Currently, part of the megaprepuce skin is used to correct the defect. A recent study shows that patients with this pathology and hypospadias present mostly defects in the muscle dartos. The investigators do not know the physiological bases of the megaprepuce, neither the clinical and aesthetics implications of this abnormal tissue for the patient, and how this affects the postoperative evolution. With the present study the investigators intended to answer these questions and to open paths for future research in this area.

NCT ID: NCT01493791 Withdrawn - Clinical trials for Urogenital Abnormalities

CDB-2914 for Abnormal Uterine Bleeding in Premenopausal Women

Start date: November 8, 2011
Phase: Early Phase 1
Study type: Interventional

Background: - CDB-2914 is a hormone that blocks progesterone, which is necessary for maintaining pregnancy. In women with fibroid tumors, CDB-2914 shrank the tumors. In many cases, menstrual periods stopped during treatment. Because CDB-2914 decreased or stopped menstrual bleeding in women with fibroids, it may be able to treat abnormal periods in women without fibroids. Objectives: - To see whether CDB-2914 can treat abnormal uterine bleeding in premenopausal women. Eligibility: - Premenopausal women who have abnormal uterine bleeding that is not caused by fibroids. Design: - Participants will be screened with a physical exam and medical history. They will also have blood and urine tests. An ultrasound with fluid of the uterus will test for fibroids. Uterine cells will be collected for biopsy. - For the next three menstrual cycles, participants will take either CDB-2914 or a placebo. Treatment will be studied with blood tests and symptom diaries. - At the end of the treatment, participants have three options. They can have surgery at the Clinical Center or have another 3 months of CDB-2914. The third option is to stop treatment at the Clinical Center. - Surgery will be either uterine ablation or hysterectomy. Only women older than age 33 may have a hysterectomy. Blood and urine samples will be collected after surgery. - Both surgery and further treatment participants will have followup exams. - All participants will have a final followup exam 1 year after stopping treatment....